Business Context and Reporting Period
Company: NovaBridge Biosciences (formerly I-Mab)
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: A global biotechnology platform company focused on precision immuno-oncology and ophthalmology. In 2025, the company executed a strategic pivot, divesting its Greater China assets in April 2024 and adopting a new business model in October 2025 to operate as a platform company with specialized subsidiaries. The company changed its name from I-Mab to NovaBridge Biosciences effective October 29, 2025.
Key Financial Metrics
| Metric | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | $0 | $0 | $0.6 million |
| Net Loss (Continuing Ops) | $(88.3) million | $(49.7) million | $(82.2) million |
| Net Loss (Total) | $(88.3) million | $(22.2) million | $(207.7) million |
| Net Loss Attributable to NovaBridge | $(46.3) million | $(22.2) million | $(207.7) million |
| Research & Development Expenses | $(62.9) million | $(21.8) million | $(21.4) million |
| Administrative Expenses | $(31.4) million | $(29.7) million | $(28.2) million |
| Cash & Cash Equivalents (End of Period) | $210.6 million | $68.3 million | $310.7 million |
| Short-Term Investments | $0.2 million | $105.1 million | N/A |
| Total Liquidity (Cash + ST Inv) | $210.8 million | $173.4 million | N/A |
| Net Cash Used in Operating Activities | $(20.6) million | $(52.7) million | $(72.7) million |
Note: 2024 and 2023 figures include discontinued operations related to the divested Greater China assets. 2025 figures reflect continuing operations only.
Material Changes vs. Prior Period
- Revenue: No revenue was generated in 2025 or 2024. The $0.6 million revenue in 2023 was from collaboration arrangements with AbbVie, which were terminated in 2023.
- Net Loss: Net loss from continuing operations increased to $88.3 million in 2025 from $49.7 million in 2024. This increase is primarily driven by the recognition of $47.1 million in In-Process Research and Development (IPR&D) expenses related to the acquisition of VIS-101 rights and $2.9 million for the Bridge Health acquisition.
- R&D Expenses: Increased significantly by $41.1 million (189%) year-over-year, largely due to the non-cash expensing of acquired IPR&D assets ($47.1 million for VIS-101 and $2.9 million for Bridge Health), partially offset by lower employee costs due to a 27% workforce reduction in 2025.
- Liquidity: Cash and cash equivalents increased to $210.6 million in 2025 from $68.3 million in 2024, bolstered by net proceeds of approximately $61.2 million from an underwritten offering of ADSs in August 2025.
- Discontinued Operations: The company ceased consolidating its Greater China assets in April 2024. Consequently, 2025 results do not include any discontinued operations, whereas 2024 included a $27.5 million gain from the sale of these assets.
Guidance, Outlook, and Risks
Outlook and Guidance
- Cash Runway: Management believes current cash, cash equivalents, and short-term investments of $210.8 million are sufficient to meet working capital requirements and capital expenditures into the fourth quarter of 2028.
- Pipeline Progress:
- Givastomig (Oncology): Positive Phase 1b data confirmed in early 2026. A global randomized Phase 2 study initiated in February 2026. The company anticipates initiating a registrational Phase 3 trial as early as Q4 2026.
- VIS-101 (Ophthalmology): Acquired via the Visara subsidiary. Positive Phase 2a data announced in March 2026. A Phase 2b study is planned for the second half of 2026, with a global Phase 3 program starting in 2027.
- Strategic Shift: The company is transitioning to a biotechnology platform model with separate subsidiaries (e.g., Visara) to manage specific therapeutic assets.
Material Risks and Contingencies
- Internal Control Weaknesses: The company identified material weaknesses in internal control over financial reporting related to ineffective information technology general controls (ITGCs). While no misstatements were identified in the 2025 financial statements, remediation is ongoing.
- Passive Foreign Investment Company (PFIC): The company believes it was a PFIC for the 2025 taxable year and likely will be for the current year, which could subject U.S. investors to adverse tax consequences.
- Regulatory and Legal:
- PRC Regulations: Ongoing risks related to data privacy, cybersecurity, and potential requirements for CSRC filings for offshore offerings.
- Legal Proceedings: A trade secret misappropriation lawsuit against Inhibrx, Inc. resulted in a jury verdict in favor of the defendants in November 2024 regarding a portion of the claims.
- Capital Needs: The company expects to continue incurring losses and will require substantial additional funding to complete development and commercialization of its drug candidates.
Key Facts for Investor Verification
- Divestiture Impact: Verify the separation of financial results between continuing operations (U.S./Global) and discontinued operations (Greater China) to ensure accurate period-over-period comparisons.
- IPR&D Expensing: Confirm the valuation methodology and assumptions used for the $47.1 million VIS-101 and $2.9 million Bridge Health IPR&D write-offs, as these significantly impacted 2025 net loss.
- Internal Controls: Monitor the progress of remediation efforts for the identified material weaknesses in IT general controls.
- Cash Position: Verify the $210.8 million liquidity figure and the projected runway to Q4 2028, considering the high burn rate associated with clinical trials.
- PFIC Status: Review the tax implications for U.S. investors given the company's self-identification as a Passive Foreign Investment Company.